论著

利用转录组二代测序探索直肠癌术前放化疗的敏感性分子特征

  • 张威 ,
  • 叶颖江 ,
  • 任仙文 ,
  • 黄晶 ,
  • 申占龙
展开
申占龙,北京大学人民医院胃肠外科主任医师、副教授、博士生导师,外科肿瘤研究室副主任。任中国医师协会外科医师分会多学科综合治疗(multi-disciplinary team, MDT)专业委员会副秘书长、青年委员会主任委员,中国医师协会外科医师分会经肛门全直肠系膜切除术专业委员会(transanal total mesorectal excision, taTME)副主任委员,中国医师协会结直肠肿瘤专业委员会taTME学组副主任委员,中国抗癌协会大肠癌专业委员会青年委员会副主任委员,中华医学会外科学分会实验外科学组委员、中国医师协会外科医师分会亚太胃肠外科研究协作组(Asian-Pacific Study Group for Gastrointestinal Surgery, APGIS)执行主席等。以第一作者或通信作者发表论文60余篇,其中SCI论文37篇,总影响因子140.617。2018年,关于结直肠癌T细胞动态变化的单细胞测序研究成果发表在Nature杂志,获得中国生物信息学十大进展称号。作为课题负责人,主持国家自然科学基金2项,北京市自然科学基金1项,北京大学临床医学+X青年专项基金1项,医院发展基金4项,国家专利7项,荣获北京大学医学部优秀科研创新奖、优秀教师,北京大学人民医院学术新星一等奖、优秀教学研究奖,优秀对外交流奖,韩国胃癌学会最佳报告奖等。临床专长:胃肠肿瘤的诊断与外科治疗,尤其是腹腔镜微创手术,包括结肠癌完整结肠系膜切除术、肛提肌外腹会阴联合切除术、直肠癌超低位保肛taTME手术、胃癌根治术。研究方向:胃肠道肿瘤侵袭转移的机制研究,尤其是与监测预后和治疗敏感性相关的分子标志物的筛选和验证研究,包括蛋白质修饰组学(乙酰化)、非编码RNA(microRNA、lncRNA、circRNA)、肿瘤微环境[肿瘤相关巨噬细胞(tumor associated macrophage,TAM)、T细胞、B细胞]等。

收稿日期: 2019-03-25

  网络出版日期: 2019-06-26

基金资助

北京大学临床医学+X青年专项(PKU2018LCXQ021)-中央高校基本科研业务费

Detection of preoperative chemoradiotherapy sensitivity molecular characteristics of rectal cancer by transcriptome second generation sequencing

  • Wei ZHANG ,
  • Ying-jiang YE ,
  • Xian-wen REN ,
  • Jing HUANG ,
  • Zhan-long SHEN
Expand

Received date: 2019-03-25

  Online published: 2019-06-26

Supported by

Supported by the Fundamental Research Funds for the Central Universities: Peking University Clinical Medicine Plus X-Young Scholars Project (PKU2018LCXQ021)

摘要

目的 探索直肠癌新辅助放化疗的敏感性分子特征。方法 前瞻性收集局部进展期中、低位直肠癌30例患者的临床病理资料,包括一般情况、放化疗前影像学资料、放化疗前活组织病理检查资料、肿瘤分化程度等9项指标,分析其与直肠癌放化疗后肿瘤消退分级(tumor regression grading,TRG)的相关性。收集这30例患者新辅助治疗前结肠镜活检冰冻标本,进行转录组二代测序和生物信息学分析,筛选可能驱动直肠癌放化疗敏感性的基因。结果 30例直肠癌患者中,病理完全缓解9例,部分缓解12例,缓解差9例。直肠癌放化疗后病理TRG缓解程度与肿瘤术前MRI的T分期呈负相关(P=0.046),与术前MRI直肠癌壁外血管侵犯(extramural vascular invasion, EMVI)呈正相关(P=0.003)。转录组二代测序对所获取的P<0.05的217条转录本进行信号通路富集分析,可以发现多条与抗原呈递相关的细胞信号转导通路,其中HSPA1A、HSPA1B和EXOSC2的高表达和术后病理缓解差呈正相关(P<0.05),DNMBP、WASH8P、FAM57A和SGSM2等的高表达和术后病理缓解良好呈正相关(P<0.05)。结论 直肠癌术前MRI检测肿瘤EMVI阳性的患者放化疗后病理完全缓解率明显优于EMVI阴性者。HSPA1A、HSPA1B和EXOSC2高表达的患者术后病理缓解差,而DNMBP、WASH8P、FAM57A和SGSM2高表达的患者术后病理缓解良好。基于直肠癌放化疗敏感性分子特征,尝试阻断或增强与直肠癌放化疗敏感性相关的分子通路,可进一步探索能增加直肠癌放化疗敏感性的候选治疗靶点。

本文引用格式

张威 , 叶颖江 , 任仙文 , 黄晶 , 申占龙 . 利用转录组二代测序探索直肠癌术前放化疗的敏感性分子特征[J]. 北京大学学报(医学版), 2019 , 51(3) : 542 -547 . DOI: 10.19723/j.issn.1671-167X.2019.03.025

Abstract

Objective: To detect the preoperative chemoradiotherapy sensitivity molecular characteristics of rectal cancer by transcriptome second generation sequencing.Methods: The clinicopathological data of 30 patients with locally advanced rectal cancer were collected prospectively, including 9 indicators (general conditions, imaging data before radiotherapy and chemotherapy, pathological data of biopsy before radiotherapy and chemotherapy, and tumor differentiation degree, etc.), in order to analyze the correlation between them and tumor regression grading (TRG) after radiotherapy and chemotherapy for rectal cancer. At the same time, frozen specimens of colonoscopy biopsy before neoadjuvant therapy were collected from these 30 patients, and transcriptome second-generation sequencing was performed for bioinformatics analysis to screen out the genes that might drive the radio chemotherapy sensitivity of rectal can-cer. Results: Among the 30 patients with rectal cancer, 9 had complete pathological remission, 12 had partial remission, and 9 had poor remission. The degree of pathological TRG remission after radiotherapy and chemotherapy for rectal cancer was negatively correlated with the preoperative MRI T stage (P=0.046), and positively correlated with preoperative MRI rectal cancer extravascular invasion (EMVI) (P=0.003). Transcriptome second-generation sequencing of the obtained 217 transcripts (P<0.05) for signal pathway enrichment analysis, and multiple cell signal transduction pathways related to antigen presentation could be found. The high expression of HSPA1A, HSPA1B and EXOSC2 was positively correlated with postoperative pathological remission (P<0.05). The high expression of DNMBP, WASH8P, FAM57A, and SGSM2 was positively correlated with postoperative pathological remission (P<0.05).Conclusion: Preoperative NMR detection of extra-tumoral vascular invasion (EMVI-positive) in patients with rectal cancer was significantly better than that of EMVI-negative patients after chemoradiotherapy. Patients with high expressions of HSPA1A, HSPA1B and EXOSC2 had poor postoperative pathological remission, while patients with high expressions of genes, such as DMNMB, WASH8P, FAM57A, and SGSM2 had good postoperative pathological remission. Based on the molecular characte-ristics of rectal cancer radiotherapy and chemotherapy, attempts to block or enhance the molecular pathways associated with chemosensitivity of rectal cancer, are to be made to further explore new candidate therapeutic targets that can increase the sensitivity of radiotherapy and chemotherapy for rectal cancer.

参考文献

[1] Park IJ, You YN, Agarwal A , et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer[J]. J Clin Oncol, 2012,30(15):1770-1776.
[2] Dworak O, Keilholz L, Hoffmann A . Pathological features of rectal cancer after preoperative radiochemotherapy[J]. Int J Colorectal Dis, 1997,12(1):19-23.
[3] R?del C, Martus P, Papadoupolos T , et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer[J]. J Clin Oncol, 2005,23(34):8688-8696.
[4] Fokas E, Liersch T, Fietkau R , et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial[J]. J Clin Oncol, 2014,32(15):1554-1562.
[5] Smith JD, Ruby JA, Goodman KA , et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy[J]. Ann Surg, 2012,256(6):965-972.
[6] Postmus I, Trompet S, Deshmukh HA , et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL choleste-rol response to statins[J]. Nat Commun, 2014,5:5068.
[7] Williamson JS, Jones HG, Williams N , et al. Extramural vascular invasion and response to neoadjuvant chemoradiotherapy in rectal cancer: influence of the CpG island methylator phenotype[J]. World J Gastrointest Oncol, 2017,9(5):209-217.
[8] Chand M, Swift RI, Tekkis PP , et al. Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer[J]. Br J Cancer, 2014,110(1):19-25.
[9] Birlik B, Obuz F, Elibol FD , et al. Diffusion-weighted MRI and MR-volumetry: in the evaluation of tumor response after preoperative chemoradiotherapy in patients with locally advanced rectal cancer[J]. Magn Reson Imaging, 2015,33(2):201-212.
[10] McCawley N, Clancy C, O’Neill BD , et al. Mucinous rectal adenocarcinoma is associated with a poor response to neoadjuvant chemoradiotherapy: A systematic review and meta-analysis[J]. Dis Colon Rectum, 2016,59(12):1200-1208.
[11] Agarwal A, Chang GJ, Hu CY , et al. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy[J]. Cancer, 2013,119(24):4231-4241.
[12] Maas M, Nelemans PJ, Valentini V , et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data[J]. Lancet Oncol, 2010,11(9):835-844.
[13] Gérard JP, Chamorey E, Gourgou-Bourgade S , et al. Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial[J]. Radiother Oncol, 2015,115(2):246-252.
[14] Chen MB, Wu XY, Yu R , et al. P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer[J]. PLoS One, 2012,7(9):e45388.
[15] D’Angelo E, Zanon C, Sensi F , et al. miR-194 as predictive biomarker of responsiveness to neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma[J]. J Clin Pathol, 2018,71(4):344-350.
[16] Agostini M, Zangrando A, Pastrello C , et al. A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients[J]. Cancer Biol Ther, 2015,16(8):1160-1171.
[17] Scott JG, Berglund A, Schell MJ , et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study[J]. Lancet Oncol, 2016,18(2):202-211.
[18] Regine WF, Winter KA, Abrams RA , et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial[J]. JAMA, 2008,299(9):1019-1026.
[19] Coveler AL, Richard P, Apisarnthanarax S , et al. Is there a best radiosensitizing agent in the treatment of locally advanced rectal cancer?[J]. Current Colorectal Cancer Reports, 2016,12(4):189-200.
[20] Aschele C, Cionini L, Lonardi S , et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the star-01 rando-mized phase Ⅲ trial[J]. J Clin Oncol, 2011,29(20):2773-2780.
文章导航

/